<?xml version='1.0' encoding='utf-8'?>
<document id="12242602"><sentence text="Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects."><entity charOffset="19-30" id="DDI-PubMed.12242602.s1.e0" text="mirtazapine" /><entity charOffset="35-44" id="DDI-PubMed.12242602.s1.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.12242602.s1.e0" e2="DDI-PubMed.12242602.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s1.e0" e2="DDI-PubMed.12242602.s1.e1" /></sentence><sentence text="The objectives of this study were to assess the effect of mirtazapine on steady-state pharmacokinetics of phenytoin and vice versa and to assess tolerability and safety of the combined use of mirtazapine and phenytoin"><entity charOffset="58-69" id="DDI-PubMed.12242602.s2.e0" text="mirtazapine" /><entity charOffset="106-115" id="DDI-PubMed.12242602.s2.e1" text="phenytoin" /><entity charOffset="192-203" id="DDI-PubMed.12242602.s2.e2" text="mirtazapine" /><entity charOffset="208-217" id="DDI-PubMed.12242602.s2.e3" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e0" e2="DDI-PubMed.12242602.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e0" e2="DDI-PubMed.12242602.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e0" e2="DDI-PubMed.12242602.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e0" e2="DDI-PubMed.12242602.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e1" e2="DDI-PubMed.12242602.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e1" e2="DDI-PubMed.12242602.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e1" e2="DDI-PubMed.12242602.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e2" e2="DDI-PubMed.12242602.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s2.e2" e2="DDI-PubMed.12242602.s2.e3" /></sentence><sentence text="" /><sentence text="This was an open-label, randomised, parallel-groups, single-centre, multiple-dose pharmacokinetic study" /><sentence text=" Seventeen healthy, male subjects completed either treatment A [nine subjects: daily 200 mg phenytoin for 17 days plus mirtazapine (15 mg for 2 days continuing with 30 mg for 5 days) from day 11 to day 17] or treatment B [eight subjects: mirtazapine, daily 15 mg for 2 days continuing with 30 mg for 15 days plus phenytoin 200 mg from day 8 to day 17]"><entity charOffset="92-101" id="DDI-PubMed.12242602.s5.e0" text="phenytoin" /><entity charOffset="119-130" id="DDI-PubMed.12242602.s5.e1" text="mirtazapine" /><entity charOffset="238-249" id="DDI-PubMed.12242602.s5.e2" text="mirtazapine" /><entity charOffset="313-322" id="DDI-PubMed.12242602.s5.e3" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e0" e2="DDI-PubMed.12242602.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e0" e2="DDI-PubMed.12242602.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e0" e2="DDI-PubMed.12242602.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e0" e2="DDI-PubMed.12242602.s5.e3" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e1" e2="DDI-PubMed.12242602.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e1" e2="DDI-PubMed.12242602.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e1" e2="DDI-PubMed.12242602.s5.e3" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e2" e2="DDI-PubMed.12242602.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s5.e2" e2="DDI-PubMed.12242602.s5.e3" /></sentence><sentence text=" Serial blood samples were taken for kinetic profiling on the 10th and 17th days of treatment A and on the 7th and 17th days of treatment B" /><sentence text=" Induction of CYP 3A by phenytoin was evaluated by measuring the ratio of 6 beta-hydroxycortisol over cortisol on the 1st, 7th and 17th days of treatment B"><entity charOffset="24-33" id="DDI-PubMed.12242602.s7.e0" text="phenytoin" /><entity charOffset="102-110" id="DDI-PubMed.12242602.s7.e1" text="cortisol" /><pair ddi="false" e1="DDI-PubMed.12242602.s7.e0" e2="DDI-PubMed.12242602.s7.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s7.e0" e2="DDI-PubMed.12242602.s7.e1" /></sentence><sentence text="" /><sentence text="Co-administration of mirtazapine had no effect on the steady-state pharmacokinetics of phenytoin, i"><entity charOffset="21-32" id="DDI-PubMed.12242602.s9.e0" text="mirtazapine" /><entity charOffset="87-96" id="DDI-PubMed.12242602.s9.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.12242602.s9.e0" e2="DDI-PubMed.12242602.s9.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s9.e0" e2="DDI-PubMed.12242602.s9.e1" /></sentence><sentence text="e" /><sentence text=" the area under the plasma concentration-time curve (AUC)(0-24) and peak plasma concentration (C(max)) remained unchanged" /><sentence text=" The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81"><entity charOffset="17-26" id="DDI-PubMed.12242602.s12.e0" text="phenytoin" /><entity charOffset="66-77" id="DDI-PubMed.12242602.s12.e1" text="mirtazapine" /><pair ddi="false" e1="DDI-PubMed.12242602.s12.e0" e2="DDI-PubMed.12242602.s12.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s12.e0" e2="DDI-PubMed.12242602.s12.e1" /></sentence><sentence text="6 ng h/ml and a mean decrease of C(max) from 69" /><sentence text="7+/-17" /><sentence text="5 ng/ml to 46" /><sentence text="9+/-10" /><sentence text="9 ng/ml" /><sentence text=" Induction of CYP 3A by phenytoin is confirmed by the significantly ( P=0"><entity charOffset="24-33" id="DDI-PubMed.12242602.s18.e0" text="phenytoin" /></sentence><sentence text="001) increased 6beta-hydroxycortisol/cortisol ratio from 1"><entity charOffset="15-36" id="DDI-PubMed.12242602.s19.e0" text="6beta-hydroxycortisol" /><entity charOffset="37-45" id="DDI-PubMed.12242602.s19.e1" text="cortisol" /><pair ddi="false" e1="DDI-PubMed.12242602.s19.e0" e2="DDI-PubMed.12242602.s19.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s19.e0" e2="DDI-PubMed.12242602.s19.e1" /></sentence><sentence text="74+/-1" /><sentence text="00 to 2" /><sentence text="74+/-1" /><sentence text="64" /><sentence text="" /><sentence text="Co-administration of mirtazapine did not alter the steady-state pharmacokinetics of phenytoin"><entity charOffset="21-32" id="DDI-PubMed.12242602.s25.e0" text="mirtazapine" /><entity charOffset="84-93" id="DDI-PubMed.12242602.s25.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.12242602.s25.e0" e2="DDI-PubMed.12242602.s25.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s25.e0" e2="DDI-PubMed.12242602.s25.e1" /></sentence><sentence text=" The addition of phenytoin to an existing daily administration of mirtazapine results in a decrease of the plasma concentrations of mirtazapine by 46% on average, most likely due to induction of CYP 3A3/4"><entity charOffset="17-26" id="DDI-PubMed.12242602.s26.e0" text="phenytoin" /><entity charOffset="66-77" id="DDI-PubMed.12242602.s26.e1" text="mirtazapine" /><entity charOffset="132-143" id="DDI-PubMed.12242602.s26.e2" text="mirtazapine" /><pair ddi="false" e1="DDI-PubMed.12242602.s26.e0" e2="DDI-PubMed.12242602.s26.e0" /><pair ddi="false" e1="DDI-PubMed.12242602.s26.e0" e2="DDI-PubMed.12242602.s26.e1" /><pair ddi="false" e1="DDI-PubMed.12242602.s26.e0" e2="DDI-PubMed.12242602.s26.e2" /><pair ddi="false" e1="DDI-PubMed.12242602.s26.e1" e2="DDI-PubMed.12242602.s26.e1" /><pair ddi="false" e1="DDI-PubMed.12242602.s26.e1" e2="DDI-PubMed.12242602.s26.e2" /></sentence><sentence text="" /></document>